A Study of Human Umbilical Cord Blood (REGENECYTE) Infusion in Patients With Post-COVID Condition
Trial statusNot yet recruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age18-65
SponsorStemCyte, Inc.
About this trial
REGENECYTE (HPC, Cord Blood) for treatment in patients with post-COVID.
Eligibility criteria
Qualifiers
Male or female aged ≥ 18
With post-COVID condition
Has had a recent (within 7 days) negative SARS-CoV-2 test (an approved PCR or antigen test)
Able to provide signed informed consent (by the subject or his/her legally authorized representative)
Disqualifiers
Neurological disorders prior to COVID-19 diagnosis
With pre-existing terminal illness
With known immune disease
Is pregnant or breastfeeding
Trial design
Treatments tested in this trial
- REGENECYTE
- Placebo
Treatment groups
60 Participants
are divided into 2 treatment groupsLocations
Sponsors and collaborators
Source ClinicalTrials.gov